



Network for Excellence  
in Health Innovation

## Innovations in Behavioral Health:

# Psychedelic Medicine: Old Compounds, New Beginnings

July 14th, 2021 | 12:00-1:30 pm ET

## Participant Bios



### Mike Apkon, MD, PhD, MBA (Moderator)

*President, Sand Street Advisors;*  
*NEHI Board Member*

Dr. Apkon is a physician executive, scientist, and healthcare leader who has served in C-level and senior leadership roles at top academic hospitals in the United States and Canada, including The Tufts Medical Center and The Floating Hospital for Children in Boston, The Hospital for Sick Children in Toronto, The Children's Hospital of Philadelphia, and the Yale New Haven Health System. Most recently as CEO of Tufts Medical Center, Dr. Apkon led a 415-bed hospital staffed by 6,000 medical staff, employees, and volunteers with a \$1 billion budget. He also oversaw Tufts' subsidiaries, including the New England Quality Care Alliance (NEQCA), a network of 1,800 physicians, and the Tufts Medical Center Physicians Organization. In his role as CEO, Dr. Apkon also served as Executive Vice President for Wellforce Health System, of which Tufts Medical Center is a founding member. Dr. Apkon is a Director at NEHI, and serves as a director for MindBeacon, a Canadian digital mental health company. He has also served as a Director for MaRS Innovation (now Toronto Innovation Accelerator Partners), an incubator serving the greater Toronto academic and healthcare innovation communities and 7D Surgical, a Toronto-based medical device company. Dr. Apkon has extensive international management experience in both pediatric and adult-oriented healthcare and has worked with organizations and governments in the UK, Europe, China, Africa, and the Middle East, as well as North America. He has consulted widely on business development, capacity development, and management systems. He is an expert in strategy, systems development, and operations management, as well as the application of lean and high reliability organizational thinking to drive improvements in quality, safety, and efficiency.



### Joy Sun Cooper

*Head of Commercialization and Patient Access*  
*MAPS Public Benefit Corporation*

Joy Sun Cooper is Head of Commercialization and Patient Access at MAPS Public Benefit Corporation. In this role she is leading the go-to-market for MDMA-assisted therapy, which is currently in Phase 3 clinical trials as a treatment for PTSD. Prior to joining MAPS PBC, Joy co-founded and served as Chief Operating Officer of Groups, a venture-backed healthcare services company that has built a network of 80+ outpatient clinics to treat opioid use disorder in rural communities. She also helped launch GiveDirectly, a global nonprofit, and served as an engagement manager at McKinsey & Company in the healthcare and agriculture practices. She started her career in global public health and served as Director of Operations at the Clinton Health Access Initiative (CHAI), where she designed and implemented large-scale HIV treatment programs in Sub-Saharan Africa. Joy holds an M.B.A. from Stanford University Graduate School of Business and a B.S. in international affairs from Georgetown University School of Foreign Service.



## Joseph del Moral

*Co-Founder and Chief Executive Officer*  
Field Trip

Joseph is a serial entrepreneur and a founder of Field Trip. He, along with Ronan Levy, Hannan Fleiman and Dr. Ryan Yermus, was a founder of CanvasRx and Canadian Cannabis Clinics, where he served as CEO. After CanvasRx Inc. was acquired by Aurora Cannabis Inc. (NYSE: ACB) in 2016, he joined Aurora's board of directors and, along with his partners, led Aurora's mergers/acquisitions and corporate development efforts. Following his time at Aurora, Joseph became CEO of Trait Biosciences Inc., a leading cannabis biotechnology company. Prior to working in cannabis, Joseph co-founded Newten Home Comfort, a fast growing home services company which was acquired by Just Energy Inc.



## Dan Grossman (Closing Remarks)

*Managing Partner*  
Boston Consulting Group

Dan joined the Boston Consulting Group in 2003, and is a Managing Director and Senior Partner in its global Health Care Practice Area, based in the Chicago office. He is responsible for the practice's portfolio of proprietary data & tools, and chairs the Diversity, Equity & Inclusion Council for BCG in the midwest. Dan works primarily with clients in the biopharmaceutical and medical technology sectors, with extensive experience in neurodegeneration, cardiovascular disease, immunology, diabetes, and a range of orphan diseases, all of which have affected people close to him. Dan's work with his clients focuses on corporate portfolio strategy, innovation pipeline development, and on the translation of breakthrough innovation to commercial success and value creation.



## John Krystal, MD

*Chair and Chief of Psychiatry*  
Yale-New Haven Hospital

Dr. Krystal is the Robert L. McNeil, Jr., Professor of Translational Research; Professor of Psychiatry, Neuroscience, and Psychology; Chair of the Department of Psychiatry at Yale University; and Chief of Psychiatry and Behavioral Health at Yale-New Haven Hospital. He is a graduate of the University of Chicago, Yale University School of Medicine, and the Yale Psychiatry Residency Training Program. He has published extensively on the neurobiology and treatment of schizophrenia, alcoholism, PTSD, and depression. Notably, his laboratory discovered the rapid antidepressant effects of ketamine in humans. He directs/co-directs the Yale Center for Clinical Investigation (CTSA), NIAAA Center for the Translational Neuroscience of Alcoholism, and Clinical Neuroscience Division of the National Center for PTSD (VA). Dr. Krystal is a member

of the U.S. National Academy of Medicine; co-director of the Neuroscience Forum of the U.S. National Academies of Sciences, Engineering, and Medicine; and editor of *Biological Psychiatry* (IF=12.1). He has served as a member of the NIMH National Mental Health Advisory Council and the NIAAA National Alcohol Advisory Council. He is past president of the American College of Neuropsychopharmacology (ACNP) and the International College of Neuropsychopharmacology (CINP).



## Neil Leibowitz, MD, JD

*Chief Medical Officer*

Beacon Health Options

Neil Leibowitz, MD, JD is the Chief Medical Officer for Beacon Health Options. In this capacity, he oversees Beacon's medical functions and the development of clinical strategies and programs. He is particularly focused on the intersection of digital health and traditional care. Previously, Neil was the Chief Medical Officer of Talkspace where he helped the company enter the enterprise market and grow to over 50 million covered lives culminating in Talkspace becoming the first publicly traded digital behavioral health services company. He has also held senior roles at Optum and at Montefiore Medical Center. Neil received his MD from New York Medical College, his JD from the New York University School of Law and his BA in Economics from Johns Hopkins University.



## Wendy Warring, JD

*President and CEO*

NEHI

Wendy Warring, J.D. is President and CEO of NEHI where she is focused on strengthening NEHI's role in advancing innovative care models and technologies that improve access to effective health care, especially by lowering individuals' health care costs. Warring previously served as Senior Vice President of Network Development and Strategic Partnerships at Boston Children's Hospital. She was responsible for developing strategies and executing operational initiatives to strengthen relationships between Boston Children's and primary care physicians, hospital systems, and other providers locally, regionally, and nationally. She has also held positions as Executive Vice President & COO at Connecticut Children's Medical Center and EVP of UMass Memorial Health Care, both positions involving the implementation of strategies to strengthen the organizations' ability to deliver accessible and affordable care. Warring has substantial experience in the public sector as well. She was the Massachusetts Commissioner of the Division of Medical Assistance where she directed the state's Medicaid program. Warring received her J.D. from Yale University and her bachelors degree from Brown University.